Empowered Patient Podcast

Justin Miller is the VP of Customer Success at eVisit and has recently returned from a tour of client sites to see how telehealth is functioning particularly in the real-world application of the Emergency Triage, Treat, and Transport (ET3) emergency medical response model. eVisit is the only end-to-end enterprise care delivery platform built for hospitals and healthcare systems with a focus on the virtual care space.

Justin explains, "So Emergency Triage, Treat and Transport is effectively a model where telehealth is now engaged in this innovative approach to care delivery. And so typically, a medic would show up after a 911 call on someone's doorstep, sometimes on the worst day of someone's life, right? But they're showing up in these situations that are sometimes things like motor vehicle accidents. Sometimes they're things like, I'm having a behavioral health crisis. Sometimes they are things like, I actually don't have a primary care physician, and I believe that I need care right away, but it isn't emergency. That whole continuum ends up making a 911 call on a regular basis."

"GMR, Global Medical Response, is the company that has effectively taken telehealth and placed it with their medics and inside ambulances. When someone shows up on scene, they can do a quick assessment and verify if this person should be transported because it's a highly emergent situation, or if this person is actually appropriate to treat via virtual care. And if indeed they are able to be treated via virtual care, they would conduct a brief intake and get that person with a doctor right away."

@eVisit #VirtualCare #DigitalHealth #Telehealth #Telemedicine

evisit.com

Listen to the podcast here

Justin Miller is the VP of Customer Success at eVisit and has recently returned from a tour of client sites to see how telehealth is functioning particularly in the real-world application of the Emergency Triage, Treat, and Transport (ET3) emergency medical response model. eVisit is the only end-to-end enterprise care delivery platform built for hospitals and healthcare systems with a focus on the virtual care space.

Justin explains, "So Emergency Triage, Treat and Transport is effectively a model where telehealth is now engaged in this innovative approach to care delivery. And so typically, a medic would show up after a 911 call on someone's doorstep, sometimes on the worst day of someone's life, right? But they're showing up in these situations that are sometimes things like motor vehicle accidents. Sometimes they're things like, I'm having a behavioral health crisis. Sometimes they are things like, I actually don't have a primary care physician, and I believe that I need care right away, but it isn't emergency. That whole continuum ends up making a 911 call on a regular basis."

"GMR, Global Medical Response, is the company that has effectively taken telehealth and placed it with their medics and inside ambulances. When someone shows up on scene, they can do a quick assessment and verify if this person should be transported because it's a highly emergent situation, or if this person is actually appropriate to treat via virtual care. And if indeed they are able to be treated via virtual care, they would conduct a brief intake and get that person with a doctor right away."

@eVisit #VirtualCare #DigitalHealth #Telehealth #Telemedicine

evisit.com

Download the transcript here

Bill Hinshaw is the President and CEO of Axcella Therapeutics, a clinical-stage biotech company founded by Flagship Pioneering, Founder of Moderna. Using their platform to create compositions of endogenous metabolic modulators, EMMs, Axcella has generated two liver programs including 1125 for treating NASH. Preclinical and clinical data led them to test 1125 for long COVID fatigue in conjunction with Dr. Betty Raman Senior Clinical Research Fellow in the Radcliffe Department of Medicine at the University of Oxford.

Bill explains, "So 1125 is a composition of amino acids and their derivatives, which is put together to address specific biologies. And we have tested it all the way into phase 2b in NASH patients. And what we've seen is it has an effect on important energy aspects, so bioenergetics, along with inflammatory redox, and immune and muscle functions."

"And what happens, in this case, is that basically, the virus comes in, hijacks the mitochondria to help it reproduce or redirect its efforts towards producing more virus. And when it does that, it damages the cell itself and its ability to create energy."

"Dr. Raman likes to talk about the fact that there's a battery, think of it as a rechargeable battery but unfortunately, in this case, the battery is damaged and it can't hold its charge. And so what 1125 is looking to do is to repair the battery's processes through areas like fatty acid oxidation, ATP generation, immune enhancement, as well as inflammatory reduction."

#Axcella #AxcellaLongCovid #AxcellaTherapeutics #OxfordLongCOVID #LongCOVID #COVID19 #COVID #ChronicFatigueLongCOVID #LongHaulers #ClinicalTrials

AxcellaTx.com

Listen to the podcast here

Bill Hinshaw is the President and CEO of Axcella Therapeutics, a clinical-stage biotech company founded by Flagship Pioneering, Founder of Moderna. Using their platform to create compositions of endogenous metabolic modulators, EMMs, Axcella has generated two liver programs including 1125 for treating NASH. Preclinical and clinical data led them to test 1125 for long COVID fatigue in conjunction with Dr. Betty Raman Senior Clinical Research Fellow in the Radcliffe Department of Medicine at the University of Oxford.

Bill explains, "So 1125 is a composition of amino acids and their derivatives, which is put together to address specific biologies. And we have tested it all the way into phase 2b in NASH patients. And what we've seen is it has an effect on important energy aspects, so bioenergetics, along with inflammatory redox, and immune and muscle functions."

"And what happens, in this case, is that basically, the virus comes in, hijacks the mitochondria to help it reproduce or redirect its efforts towards producing more virus. And when it does that, it damages the cell itself and its ability to create energy."

"Dr. Raman likes to talk about the fact that there's a battery, think of it as a rechargeable battery but unfortunately, in this case, the battery is damaged and it can't hold its charge. And so what 1125 is looking to do is to repair the battery's processes through areas like fatty acid oxidation, ATP generation, immune enhancement, as well as inflammatory reduction."

#Axcella #AxcellaLongCovid #AxcellaTherapeutics #OxfordLongCOVID #LongCOVID #COVID19 #COVID #ChronicFatigueLongCOVID #LongHaulers #ClinicalTrials

AxcellaTx.com

Download the transcript here

Dr. Betty Raman is the Senior Clinical Research Fellow in the Radcliffe Department of Medicine at the University of Oxford and has been studying the effects of COVID-19 since the pandemic began to better understand the effects of COVID on multiple organ systems.

Betty elaborates, "At Oxford, we've led a program where hundreds of patients recovering from COVID-19 volunteered to participate in our study. We undertook comprehensive assessments on magnetic resonance imaging, as well as cardiopulmonary exercise testing and blood tests."

"What has come out from all this work is that a significant proportion of people recovering from moderate to severe and even mild COVID continue to experience lingering symptoms of fatigue, pain in various parts of the body, breathlessness and difficulty breathing. Some patients also report post-exertional breathlessness, post-exertional malaise."

"So, we were quite interested in this new drug that Axcella wanted to test out, which had potential benefits for mitochondrial dysfunction, which we think may be playing a role in some symptoms that long COVID patients have experienced. And so, we have designed a study, which is aimed at fatigue dominant long COVID patients who are recovering from COVID-19 and continue to experience symptoms of fatigue. And we're going to see whether this new treatment has any effects on symptoms of fatigue in patients."

@BR_CMR #LongCovid #ChronicFatigueLongCovid #OxfordLongCovid #AxcellaLongCovid #LongHaulers #COVID19 #COVID #ClinicalTrials

Rdm.ox.ac.uk

Listen to the podcast here

Dr. Betty Raman is the Senior Clinical Research Fellow in the Radcliffe Department of Medicine at the University of Oxford and has been studying the effects of COVID-19 since the pandemic began to better understand the effects of COVID on multiple organ systems.

Betty elaborates, "At Oxford, we've led a program where hundreds of patients recovering from COVID-19 volunteered to participate in our study. We undertook comprehensive assessments on magnetic resonance imaging, as well as cardiopulmonary exercise testing and blood tests."

"What has come out from all this work is that a significant proportion of people recovering from moderate to severe and even mild COVID continue to experience lingering symptoms of fatigue, pain in various parts of the body, breathlessness and difficulty breathing. Some patients also report post-exertional breathlessness, post-exertional malaise."

"So, we were quite interested in this new drug that Axcella wanted to test out, which had potential benefits for mitochondrial dysfunction, which we think may be playing a role in some symptoms that long COVID patients have experienced. And so, we have designed a study, which is aimed at fatigue dominant long COVID patients who are recovering from COVID-19 and continue to experience symptoms of fatigue. And we're going to see whether this new treatment has any effects on symptoms of fatigue in patients."

@BR_CMR #LongCovid #ChronicFatigueLongCovid #OxfordLongCovid #AxcellaLongCovid #LongHaulers #COVID19 #COVID #ClinicalTrials

Rdm.ox.ac.uk

Download the transcript here

Dr. Antonia Chen is the Director of Research for the Division of Adult Reconstruction and a surgeon performing total joint arthroplasty in the Department of Orthopedic Surgery at Brigham and Women's Hospital. In addition to informing surgeons and other healthcare professionals about ways to avoid surgical site infections, Antonia emphasizes there is also a need to educate patients about preoperative actions to optimize them for surgery.

Antonia explains, "Surgical site infections unfortunately still plague us today, and they basically are infections that happen after surgery. It can happen in any patient and after any surgery. There are some surgeries that have a higher likelihood of it and some surgeries that don't. What happens is that after we make a cut through the skin due to surgery, the bacteria on your skin that is natural can actually get into your wound and potentially cause a surgical site infection or SSI."

"It's really nice to have something inside the wound to prevent the bacteria from growing. So Ethicon has a Plus Antibacterial suture, and it is the only commercially available suture that can prevent persistent risk from surgical infection by reducing the risk of infection."

"I really appreciate Ethicon for putting together a campaign they call Zero Starts With One. The idea is that we want to go to zero surgical site infections, and it starts with one person at a time, one prevention at a time, one patient, one healthcare provider at a time."

@BrighamWomens #SurgicalSiteInfections #ZeroStartsWithOne #Ethicon

brighamandwomens.org

Listen to the podcast here

Dr. Antonia Chen is the Director of Research for the Division of Adult Reconstruction and a surgeon performing total joint arthroplasty in the Department of Orthopedic Surgery at Brigham and Women's Hospital. In addition to informing surgeons and other healthcare professionals about ways to avoid surgical site infections, Antonia emphasizes there is also a need to educate patients about preoperative actions to optimize them for surgery.

Antonia explains, "Surgical site infections unfortunately still plague us today, and they basically are infections that happen after surgery. It can happen in any patient and after any surgery. There are some surgeries that have a higher likelihood of it and some surgeries that don't. What happens is that after we make a cut through the skin due to surgery, the bacteria on your skin that is natural can actually get into your wound and potentially cause a surgical site infection or SSI."

"It's really nice to have something inside the wound to prevent the bacteria from growing. So Ethicon has a Plus Antibacterial suture, and it is the only commercially available suture that can prevent persistent risk from surgical infection by reducing the risk of infection."

"I really appreciate Ethicon for putting together a campaign they call Zero Starts With One. The idea is that we want to go to zero surgical site infections, and it starts with one person at a time, one prevention at a time, one patient, one healthcare provider at a time."

@BrighamWomens #SurgicalSiteInfections #ZeroStartsWithOne #Ethicon

brighamandwomens.org

Download the transcript here

Dan Greenleaf is the President and CEO of Modivcare and is presenting a complete solution for vulnerable patients whose healthcare outcomes are most affected by recognized social determinants of health.

Dan elaborates, "But our view is it's not necessarily about the clinical intervention. It's about having access to the healthcare system through transportation. It's about getting a nutritious meal on a daily basis or meals on a daily basis. It's about in the event you need somebody to help you with activities of daily living that we can provide that member a caregiver. Or it's about remote monitoring where we have a way to be in kind of a constant conversation with that patient about whether it be their vitals, whether it be about medications, or whether it be about personal emergency response systems."

"We're a one-of-a-kind company doing what we're doing right now. I joined this company two years ago. It was largely a transportation company, but it did have access to 25 million lives at the time. We're 30 million now. And it became abundantly clear to me that our payers, our states, our members, our case managers all want a holistic solution and a one-stop-shop for our members."

@Modivcare #SupportiveCare #SocialDeterminantsofHealth #SDOH #HealthEquity #PersonalCare #RemotePatientMonitoring #RPM #nemt #FoodInsecurity

Modivcare.com

Listen to the podcast here.

Dan Greenleaf is the President and CEO of Modivcare and is presenting a complete solution for vulnerable patients whose healthcare outcomes are most affected by recognized social determinants of health.

Dan elaborates, "But our view is it's not necessarily about the clinical intervention. It's about having access to the healthcare system through transportation. It's about getting a nutritious meal on a daily basis or meals on a daily basis. It's about in the event you need somebody to help you with activities of daily living that we can provide that member a caregiver. Or it's about remote monitoring where we have a way to be in kind of a constant conversation with that patient about whether it be their vitals, whether it be about medications, or whether it be about personal emergency response systems."

"We're a one-of-a-kind company doing what we're doing right now. I joined this company two years ago. It was largely a transportation company, but it did have access to 25 million lives at the time. We're 30 million now. And it became abundantly clear to me that our payers, our states, our members, our case managers all want a holistic solution and a one-stop-shop for our members."

@Modivcare #SupportiveCare #SocialDeterminantsofHealth #SDOH #HealthEquity #PersonalCare #RemotePatientMonitoring #RPM #nemt #FoodInsecurity

Modivcare.com

Download the transcript here.